Evidence Synthesis
GlaxoSmithKline (GLAXO) experienced a strong shift in its financial performance, with its gross margin accelerating to 64.2%, up from 29.8%.
Loading stock analysis…
Loading stock analysis…
Evidence Synthesis
Last synthesized: 18 Sept 2026, 00:45
See how this stock's evidence score moved across recent sessions — unlock Pro for the live chart.
Full momentum history unlocks with Pro or Research.
Evidence Synthesis
GlaxoSmithKline (GLAXO) experienced a strong shift in its financial performance, with its gross margin accelerating to 64.2%, up from 29.8%.
Source observations behind the synthesis narrative.
| Metric | Value | Trend | |
|---|---|---|---|
| GROSS_MARGIN | 64.2 % | 29.8 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 29.8 % | 27.01 | ▲ |
| REVENUE_GROWTH_YOY | 16.6 % | 15.7 | ▲ |
| EPS_ACTUAL | 14 INR | — | - |
| EPS_SURPRISE_PERCENT | 0.007 % | — | - |
| PRICE_CHANGE_PERCENT | -1.971 % | — | - |
| DAILY_VOLUME | 28,736 shares | 1,20,242 | ▼ |
| CLOSE_PRICE | 2,799.9 INR | 2,856.2 | ▼ |
| NEWS_SENTIMENT_SCORE | 0.75 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 1 count | 2 | ▼ |
| TARGET_PRICE_PREMIUM | 10.04 % | — | - |